Lanreotide depot deep subcutaneous injection: a new method of delivery and its associated benefits
John D CarmichaelDepartment of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USAAbstract: Acromegaly is a rare disease characterized by excessive growth hormone secretion, usually from a pituitary tumor. Treatment options include surgery, medical therapy, and in some cases, radiation thera...
Main Author: | Carmichael JD |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2012-01-01
|
Series: | Patient Preference and Adherence |
Online Access: | http://www.dovepress.com/lanreotide-depot-deep-subcutaneous-injection-a-new-method-of-delivery--a9075 |
Similar Items
-
Treatment with Lanreotide Depot Following Octreotide Long-Acting Release Among Patients with Gastroenteropancreatic Neuroendocrine Tumors
by: Muhammad Wasif Saif, et al.
Published: (2018-10-01) -
Gluteal Subcutaneous Atrophy After Depot Steroid Injection for Allergic Rhinitis
by: Rohan Ameratunga, MBChB
Published: (2012-01-01) -
Verträglichkeit und Wirksamkeit der medikamentösen Therapie der Akromegalie mit den Depot- Somatostatinanaloga Lanreotide Autogel® und Pasireotide LAR
by: Hoffmann, Stephan
Published: (2010) -
Medikamentöse Langzeittherapie akromegaler Patienten mit Lanreotid Autogel
by: Kretschmar, Konrad
Published: (2008) -
Lanreotide-SDS micelle interactions via NMR spectroscopy
by: Chi-liang Lai, et al.
Published: (2008)